MoonLake Immunotherapies is focused on developing innovative therapies for serious inflammatory diseases, particularly those driven by the over-expression of interleukins IL-17A and IL-17F. Their lead investigational product, Sonelokimab, is a novel Nanobody® designed to target these interleukins, which play a significant role in conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis. The unique structure of Sonelokimab, which consists of three variable heavy-chain domains, allows it to selectively bind to IL-17A and IL-17F, inhibiting the formation of inflammatory dimers that contribute to disease pathology. This targeted approach aims to enhance treatment efficacy and improve patient outcomes by directly addressing inflammation in hard-to-reach tissues.

The company is advancing Sonelokimab through multiple clinical trials, including Phase 3 programs for hidradenitis suppurativa and psoriatic arthritis. Their research emphasizes the potential of Nanobody® technology to revolutionize immunotherapy by offering advantages over traditional antibodies, such as improved tissue penetration, stability, and the ability to create multivalent therapeutic molecules. MoonLake's commitment to addressing unmet medical needs in inflammatory diseases is underscored by their ongoing clinical studies and positive regulatory feedback from health authorities, positioning Sonelokimab as a promising candidate in the field of immunotherapy.

Switzerland

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

Immune System Diseases

Inflammatory disorders

Musculoskeletal Diseases

Skin Diseases

MoonLake Immunotherapies

Hidradenitis suppurativa

<p class="font_7">Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three VHH domains covalently linked by flexible &nbsp;glycine-serine spacers. With two domains, sonelokimab selectively binds &nbsp;with high affinity to IL-17A and IL-17F, thereby inhibiting the &nbsp;IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to &nbsp;human albumin, facilitating further enrichment of sonelokimab at sites &nbsp;of inflammatory edema.</p>

MoonLake Immunotherapies

Company Details